Latest

Pharmalot Ed Silverman

STAT Plus: Dutch health minister won’t cover a Gilead cancer drug due to the cost

Pharmalot Ed Silverman

STAT Plus: NIH releases data showing more clinical trial sponsors are reporting results, but most miss deadlines

Health Isabella Cueto

New lupus partnership with FDA aims to end drug trials’ history of failure

Health Helen Branswell

Cases of Marburg going unreported in Equatorial Guinea, WHO says

In the Lab Jason Mast

STAT Plus: New research may give geneticists a long-sought tool: a targeted protein delivery device

Health Elaine Chen

STAT Plus: British Columbia to bar Americans from buying Ozempic over supply concerns

Health Geoff Mulvihill — Associated Press

FDA approves over-the-counter Narcan. Here’s what it means

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development

Health Tech Lizzy Lawrence

STAT Plus: Medical device companies now need to prove to FDA they’re protected against cyberattacks

Pharmalot Ed Silverman and Damian Garde

STAT Plus: Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs

Biotech Betsy Ladyzhets

Under pressure, biotech and pharma grapple with how to take climate action

First Opinion Noura Abul-Husn

Why the rise of DNA testing is creating challenges — and an opportunity

Politics Sarah Owermohle

Republicans press Becerra on gender-affirming care, reproductive rights

Health Helen Branswell

Focus Covid booster campaigns on high-risk people, WHO’s vaccine experts recommend

Business Casey Ross

STAT Plus: Oscar Health names former Aetna executive as new CEO

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Ohio attorney general accuses PBMs of price fixing; how cost-effectiveness fight could hobble drug price negotiations

Biotech Adam Feuerstein

STAT Plus: With new study data, Intra-Cellular could expand use of approved mood-disorder treatment

Biotech Matthew Herper

STAT Plus: Viking Therapeutics releases early but promising weight loss data on new GLP-1 drug

First Opinion Colin Puzo Smith

Biden’s budget boosts funds for future pandemics, but cuts them for current ones

Special Report Brittany Trang

STAT Plus: As AI promises to revolutionize medical note-taking, concerns mount about accuracy and harm

Special Report Lev Facher

How the drug industry uses fear of fentanyl to extract more profit from naloxone

First Opinion Megan Sandel and Charlotte Bruce

Rolling back SNAP benefits puts millions of children at risk of hunger and long-term health consequences

Politics Sarah Owermohle

STAT Plus: Could a fight over cost-effectiveness upend Medicare drug price negotiation before it’s begun?

Biotech Matthew Herper

STAT Plus: Novartis data set up multibillion-dollar battle over breast cancer drugs

Health Benedict Carey

A half century after Prozac, a new generation of depression drugs is bringing hope to a long-stagnant field

Pharmalot Ed Silverman

STAT Plus: Ohio attorney general accuses pharmacy benefit managers of drug price fixing

STAT Staff

Treating Depression: A new era of promising drugs

Matt's Take Matthew Herper

STAT Plus: Bernie Sanders’ accidentally great drug pricing idea

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA proposes more rigorous cancer drug trials for accelerated approval; insurers not covering obesity meds for kids